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The Rise of Clostridium difficile in Florida
Owen Bendixsen
ABSTRACT
Clostridium difficile, a bacterium that causes diarrhea in hospitalized
patients, is on the rise in the United States as well as in other countries. This
study was done to determine the extent of the problem in Florida’s acute care
hospitals. The Agency for Healthcare Administration (AHCA) provided data for
patients discharged from Florida’s acute care hospitals for the years 1998 through
2004.
This study will focus on changes in the prevalence of Clostridium
difficile associated disease (CDAD) over time. The mortality and morbidity of
patients that have CDAD will also be examined to show if the disease is
increasing over time. Factors investigated in this study that may influence the
prevalence of CDAD include gender, race, length of hospital stay, age, and the
cost per patient discharged.
In Florida the prevalence of CDAD has risen from 3.41 per 1,000
discharged patients in 1998 to 8.11 per 1,000 discharged patients in 2004. The
mortality increased from 9.48% for CDAD positive patients in 1998 to 10.11%
for CDAD positive patients in 2004. Age plays a role in both the prevalence and
mortality of this disease. In 2004 the mortality of patients who were positive for
x

Clostridium difficile was 4.1% for those individuals that were 30-40 years old
compared to 0.54% mortality for those patients in the same age group that did not
have CDAD. The corresponding mortality for the patients aged 70-80 for the year
2004 was 11.1% for persons who had CDAD and 3.58% mortality for patients
discharged with no CDAD.
The analysis showed that CDAD prevalence is increasing in Florida
acute care hospitals. During 1998-2004 mortality rates for patients diagnosed
with CDAD is also increasing. This analysis also indicates that age is a factor that
increases the death rates for patients that are CDAD positive. A more concerted
effort to implement hospital techniques that prevent the increasing prevalence of
Clostridium difficile in Florida hospitals is recommended.

xi

Chapter One: Introduction
Clostridium difficile associated disease (CDAD) is the most common cause of
nosocomial associated diarrhea (Mylonakis, Ryan, & Calderwood, 2001). In recent
years, a noted increase in prevalence of CDAD has been documented in developed
countries (Valiquette, Low, Pepin, & McGeer, 2004). This disease increase generates a
concern for the well being of persons that are admitted to hospitals.
The two most notable increases of prevalence for this disease have been
documented in Canada and the United States (US) (Valiquette et al, 2004).
Encompassing the years 2002 to 2004 a region of Quebec, Canada experienced an
increase from 2.1 discharges per 1000 admissions to a projected 18 discharges per 1000
by the end of 2004 (Valiquette et al, 2004). The increasing number of patient discharges
positive for CDAD is not the only concern. Another concern is that the reports also show
increasing death rates from this disease. In a region of Quebec, Canada the death rate
from CDAD within 30 days after diagnosis increased from 4.7% in 1991/1992 to 13.8%
in 2003 (Pepin, Valiquette, & Cossette, 2005c).
Recognizing that Clostridium difficile infections are increasing has prompted
researchers from the US to evaluate the extent of increasing CDAD in this country.
McDonald and his colleagues noticed that since 1996 the prevalence of CDAD has risen
from 31 per 100,000 persons in 1996 to 61 per 100,000 in 2003 (McDonald, Owings, &
Jernigan, 2006). McDonald et al also noted that age as a factor that increases the
1

prevalence of CDAD. For persons > 64 the prevalence of CDAD increased from 150 per
100,000 population in 1996 to over 325 discharges per 100,000 in 2003 (McDonald et al,
2006).
The CDAD increasing prevalence in the US has caused some researchers to
investigate the extent of this problem at the state level. Florida is projected by 2010 to
have over 3.5 million people that are 65 years and older (McCharen, 2000). Increasing
CDAD prevalence in hospitals makes this disease a concern for doctors that are treating
geriatric patients. McDonald et al noted that the region of the US that includes Florida
has shown an increase in prevalence of CDAD from 20 per 100,000 persons in 1996 to
over 40 per 100,000 persons in 2003 (McDonald et al, 2006).
This study will use a cross sectional study type format to determine the
prevalence of Clostridium difficile for patients discharged from acute care hospitals in
Florida. The cross sectional study format is the best format for providing this
information on the prevalence of CDAD in Florida and will provide ideas for further
research that is needed to reduce this disease in Florida. The AHCA data contains
primary and secondary diagnose codes. These codes are presented in the data using the
International Classification of Disease, 9th revision (ICD-9) format. The ICD-9 code for
CDAD is ‘00845’ and a discharged patient is considered positive for this disease if the
code is present in either the primary or secondary diagnosis code (Hart & Hopkins,
2004).
The questions that this research will answer include:
Question 1. Is the CDAD prevalence increasing in Florida?
Question 2. Are the mortality rates among CDAD patients increasing in Florida?
2

Question 3. Is patient age a contributing factor for increasing CDAD prevalence in
Florida?
Question 4. Are patients with CDAD showing an increase in morbidity from the disease
through the years of this study?
Question 5. Can an assumption be made as to when the ‘more virulent’ strain of
Clostridium difficile entered Florida?
Other factors discussed are the change in length of hospital stay for patients that
are infected with CDAD, and if gender and racial ethnicity play a role in being more
susceptible to Clostridium difficile. These factors will be addressed in an effort to
explain the prevalence of CDAD in Florida.
Although both antibiotics and infection control practices are pertinent topics for
CDAD, unfortunately the AHCA data does not allow for a way to measure how these two
factors are affecting hospitals in Florida. Information on these two subjects will be
provided to give a more complete background of the disease and the direction some of
the research is headed.
Information for this study was extracted from AHCA data. This study uses the
hospital discharge data portion of the AHCA data. The data set includes all of the
patients discharged from Florida’s acute care hospitals, not including federal hospitals.
This study has been designed to research the effect of CDAD prevalence on patients
discharged from Florida’s acute care hospitals.

3

Chapter Two: Background on Clostidium difficile.
HISTORY
Clostridium difficile is an anaerobic spore forming gram-positive rod that is the
most common cause of nosocomial associated diarrhea. Originally named Bacillus
difficilis, Clostridium difficile was first described in the mid-1930s (Voth & Ballard,
2005). This bacterium typically has been considered a nuisance causing minor amounts
of disease and delaying patients discharge from the hospital by a few days. In 1978,
Clostridium difficile was identified as the primary cause of psuedomembranous colitis
and was proven to be a primary isolate from the feces of humans undergoing clindamycin
therapy (Voth & Ballard, 2005). Typically, Clostridium difficile has been difficult to
remove from a hospital setting because of its spore production that allows the bacterium
to survive longer in this environment. Testing for the bacteria has been difficult and
labor intensive in the past. Many new tests have been invented to make recognition of
the disease quicker and easier.
A report by the Canadian Medical Association discusses that the old style
hospitals in Canada were not equipped to care for Clostridium difficile patients
(Eggertson, 2005). Eggertson’s paper contains quotes from other articles that hospitals
built 100 years ago were not capable of curtailing a hospital induced problem like
Clostridium difficile (Eggertson, 2005). Eggertson’s article also discusses that some
Canadian medical professionals are downplaying the increased prevalence of Clostridium
4

difficile (Eggertson, 2005). At the beginning of the 21st century the prevalence of CDAD
in hospitals seemed to change and the first inklings of these changes started to appear in
peer reviewed journals. Eggertson reports that at this time, especially in Montreal, a
significant amount of increased patient discharges with CDAD started to occur together
with an increase in deaths due to Clostridium difficle (Eggertson, 2005). Some authors
have even labeled the problem as an epidemic (Eggertson, 2005). This bacterium is now
starting to garner more press worldwide and has started to raise concerns because of
increased prevalence of CDAD in more and more countries. These facts are one of the
major reasons this research project is being done.
CLINICAL FEATURES
Clostridium difficile associated disease
Clostridium difficile manifests itself most readily as Clostridium difficile
associated disease. Onset of symptoms usually occurs in 5-10 days after antibiotic use,
but ranges from 1 day to up to 10 weeks after antibiotics are stopped (Oldfield, 2004).
The extremes of the ranges (1 day and 10 weeks) for onset of symptoms are rare.
Clinical symptoms include watery diarrhea, fever, loss of appetite, nausea, and abdominal
pain/tenderness (CDC Clostridium difficile: Information for healthcare providers, 2005).
This disease is the only nosocomial diarrhea from the Clostridium family that should
readily be screened for in hospital settings (Heimesaat, Gransow, Leidinger, & Liesenfeld
2005).
Once the bacterium is in the intestinal tract it causes disease by secreting toxins.
These toxins cause the problems associated with infections from Clostridium difficile,
and also provide the means to more readily detect the disease (Voth & Ballard, 2005).
5

These toxins lead to more problems and contribute to a higher virulence of the bacterium.
The other complications of the disease are asymptomatic colonization, diarrhea, pseudomembranous colitis, sepsis, toxic megacolon, colonic perforation, and death (CDC
Clostridium difficile: Information for healthcare providers, 2005). Other conditions
associated with the bacteria that cause more severe problems are white blood cell count
of >20,000 or less than 1500 cells/mm cubed, abdominal pain associated with a preexisting condition or post-operatively, or the presence of bowel wall thickening and
ascites (determined by CT or abdominal radiography) (McEllistrem, Carman, Gerding, &
Zheng, 2005).
Asymptomatic colonization is believed to be as high as 5% in normal adults.
Some reports from long term care facilities set the disease carrier rate higher, but the
numbers vary depending on the facilities pooled (Simor et al, 2002). Other reports show
that this rate in adults may be as high as 20% of the people cultured (Oldfeild, 2004).
This rate seems high compared to other published reports, but it is mentioned here to
show the diversity of CDAD carrier rates. A person may carry the bacteria in their colon
and not exhibit any symptoms and then in 2 months spontaneously defecate the
remaining bacteria and not be a carrier.
Pseudo-membranous colitis
One of the symptomatic signs of CDAD is the presence of psuedo-membranous
colitis. The detection of psuedo-membranes is a highly specific indicator of CDAD and
almost pathognomonic of the disease (Bouza, Munoz, & Alonso, 2005).
Pseudomembranous colitis appears in less than 25% of the discharges of CDAD, and is
characterized by white-yellowish plaques present anywhere in the colon (Bouza et al,
6

2005). Pseudomembranous colitis is a good sign that the disease is present, but as stated
does not always occur and would require a very invasive test to prove that it is present.
Perforated Colon and Toxic Megacolon
Some manifestations of Clostridium difficile in advanced stages are toxic
megacolon and perforated colon. Toxic megacolon is a dilated colon with abdominal
distention that is usually manifested in Crohn’s disease and ulcerative colitis patients
(Nayer, Vetrivel, McElroy, Pai, & Koerner, 2005). The usual symptoms consistent with
toxic megacolon are hemorrhagic and necrotic colitis from caecum to lower sigmoid
colon sparring of the rectum. Toxic megacolon can become very dangerous and can lead
to bowel surgery to repair the damage. In CDAD patients toxic megacolon is rare, but is
a recognized complication (Nayar, Vetrivel, McElroy, Pai & Koerner, 2005). Perforated
colon is another advanced stage of CDAD causing perforations in the wall of the colon.
Septicemia
Septicemia occurs when bacteria enters the bloodstream and causes an infection.
This condition is very serious and if not treated can cause death. The treatment for
septicemia is antibiotics. This condition, when discussing CDAD, can be caused by the
disease or the treatment for septicemia can lead to an infection with Clostridium difficile.
Septicemia is a problem inherent when using hospital discharge data, because the time for
onset of septicemia is not recorded in the records.
Death
The increase in deaths of patients that have been diagnosed with CDAD is a
growing concern in Canada, United States, United Kingdom and other countries.
McDonald and his colleagues reviewed the mortality from this disease for the year 2000
7

and 2003. They found that although the number of deaths had risen from 8000 in the
year 2000 to 15000 in the year 2003, the percent mortality did not rise significantly in the
years 2000 to 2003 (McDonald et al, 2006). Researchers have begun to notice that death
is becoming a more common occurrence among patients that have Clostridium difficile.
Death occurs in CDAD patients when the bacteria become too much for the body to
recover from the disease or the treatment is ineffective. It is feasible that patients with
Clostridium difficile could have other illnesses that predispose them for death.
EPIDEMIOLOGY
Age
A majority of the literature examined suggests that age is an important factor
causing CDAD. An older patient is more likely to contract the disease (McDonald et al,
2006). The age factor is compounded by the fact that older people are more likely to be
hospitalized. Increasing a person’s stay-time in a hospital increases the likelihood that
the person will be introduced to the bacteria.
The other extreme, neonate and pediatric patients, have a low prevalence for
CDAD (Tang, Roscoe, & Richardson, 2005). The interesting fact about neonates is that
they tend to have higher colonization of the bacteria, as high as 64%, in their bowels, but
the prevalence of CDAD in neonates is low (Tang et al, 2005). Tang and his colleagues
recommended that routine testing of infants for Clostridium difficile is not necessary
because of the low occurrence of disease among this age group (Tang et al, 2005).
Gender and Racial Distributions
Gender and racial distributions do not appear to predispose anyone for CDAD.
No literature was found that suggested a factor associated with Clostridium difficile for
8

any gender or racial group to have a higher frequency of this disease than any other
group. This makes sense because Clostridium difficile is caused by a bacterium that
affects hospitalized patients, independent of gender or race.
Geographical distribution
An article by the Canadian medical association journal reported that too many
hospitals in Montreal are battling outbreaks of Clostridium difficile (Eggertson &
Sibbald, 2004). This report has been followed by other reports from Canada attempting
to define the CDAD problem and why it is occurring. Another researcher from the
Netherlands discusses outbreaks occurring in his country and refers to similar problems
that the United Kingdom (UK), Canada, and the United States (US) are experiencing
(Brierley, 2005). The CDAD problem is also reported by a researcher in Sweden
indicating that this country is also experiencing an increasing prevalence of CDAD
(Noren, 2005). These reports suggest that the prevalence of this disease is increasing and
according to published reports occurs more frequently in developed countries. Therefore,
the findings of this research paper that focuses on data generated in Florida may provide
important information about CDAD prevalence.
Pre-existing medical conditions
Another factor considered for the epidemiology of CDAD is pre-existing medical
conditions. Similar to the age factor, pre-existing complications from other diseases
appear to create conditions for contracting CDAD. Any medical condition that requires a
person to be placed on antibiotics and to have a prolonged stay in the hospital will
increase a persons risk for an infection with Clostridium difficile. The risk of developing
CDAD as a hospital outpatient is about 7.7 discharges per 100,000 patients, while the
9

inpatient risk rate can be as high as 25 to 60 discharges per 100,000, depending on the
antibiotics used (Mylonakis et al, 2001).
One pre-existing condition that is believed to cause CDAD is the use of proton
pump inhibitors (PPI). PPI are drugs that attempt to reduce the amount of acidity in the
stomach. One such drug is Nexium®. Some authors believe that this class of drugs has
contributed to the increasing prevalence of CDAD (Dial, Alrasadi, Manoukian, Huang, &
Menzies, 2004; Kazakova, et al, 2006). Other researchers have noted PPI use, as a cause
of increase in CDAD discharges, is heavily confounded by length of hospital stay and age
of the patient (Pepin et al, 2005b). Other researchers found that PPI use did not
significantly cause increases in CDAD (Loo et al, 2005). In an effort to look into
community acquired CDAD, researchers are continuing to look at gastric acid and
suppressive agents (such as PPI) as reasons why more persons that have no history of
being in a hospital might be contracting CDAD (Dial, Delaney, Barkun, & Suissa, 2005).
More research into this topic needs to be performed to make an accurate assessment of
the affect of PPI on CDAD prevalence.
MICROBIOLOGY
The primary effect of Clostridium difficile on the human body are the production
of two toxins produced during bacterial secretion. These toxins secreted by Clostridium
difficile are labeled toxin A and toxin B. Toxin A is considered an enterotoxin and
cytotoxin and toxin B is a cytotoxin (McDonald et al, 2006; Gerding, 2005). These
toxins are considered the main virulence factors for the disease. The enterotoxin (toxin
A) causes disease by increasing the release of water, which will lead to an increase in the
release of electrolytes. This increase in the release of both electrolytes and water leads to
10

the diarrhea portion of the disease. The cytotoxin (both A and B) acts by killing
neighboring cells that will in turn cause the inflammation associated with the disease.
Some evidence is provided, however, that patients having no toxin A and having toxin B
still have the disease (Voth & Ballard, 2005).
The toxins of Clostridium difficile are increasingly becoming important in
identifying the extent of the disease. Voth and Ballard quoted that a relationship has been
proven to exist between toxin levels and development of psuedomembranous colitis
(Voth & Ballard, 2005). These toxins have also been important in the genetic mapping of
the organism. Mapping of the organism, in the future, may lead to new mechanisms to
limit the growth of the organism.
Clostridium difficile will grow in an anaerobic environment on normal blood agar,
but this process is time consuming and other tests have been developed that shorten the
time required for detecting CDAD toxin production (Voth & Ballard, 2005). Spore
production readily occurs in a hospital environment. These spores carry the bacteria in a
capsule that can withstand environmental pressures for many weeks and even months in
some charges (Gerding, Johnson, Peterson, Mulligan & Silva, 1995). These spores are
highly resistant to disinfectants and cleaning procedures.
TRANSMISSION
The most likely transmission of Clostridium difficile occurs from the hands of
hospital personnel, fomites, or the environment surrounding hospital or nursing home
buildings (Simor et al, 2002). Therefore, locating the sources of this bacterium in
hospitals is very important. A patient who has Clostridium difficile and shares a room
with a patient who uses antibiotics increases the CDAD prevalence for the antibiotic user
11

(McConnell, 2002). Also, a person that shares bathroom facilities with an infected
CDAD patient has an increased prevalence for CDAD. If the hospital facilities are not
properly cleaned or the infected patients are not detected and isolated appropriately, then
patients who share rooms with CDAD patients will have a significantly higher chance of
contracting CDAD.
In Canada, Pepin and his colleagues have observed that the infrastructure of some
of the Canadian hospitals contributed to the problem they are having with Clostridium
difficile (Pepin et al, 2005b). Pepin and his colleagues refer to conditions such as old
plumbing, walls that are decaying, and 4 to 6 patients per room as some of the
infrastructure problems that persist in the hospitals of Quebec, Canada (Pepin et al,
2005b). Pepin also notes that the population of Quebec is aging, and along with an
increased use of alcohol hand rubs, may have led to the increase in discharges noted in
that country (Pepin et al, 2005b). Hospital objects that tend to carry the disease are
commodes, bathing tubs, and electronic thermometers. These objects need to be
monitored closely because of their propensity to carry spores of the bacteria (Gerding et
al, 1995). Besides antibiotics, chemotherapeutic agents also seem to place patients at risk
for the disease (Gerding, 2005).
DIAGNOSIS
In the past, diagnosis of Clostridium difficile relied solely on culture for detection.
Patients with leukocytosis and hypoalbuminemia associated with their diarrhea should be
considered candidates to test for the presence of Clostridium difficile toxins in their stool
(Oldfield, 2004). The current hospital laboratory detection method is direct testing by
enzyme immunoassay for toxin A and/or B which has a sensitivity and specificity of 8812

93% and 99-100% respectively (Tang et al, 2005; Russmann, Panthel, Bader, Schmitt, &
Schaumann, 2007). This test provides a much more rapid detection of the bacteria.
Patients in a hospital that are on antimicrobial therapy and discharge 3 or more watery or
unformed stools in a 24 hour period should be tested for Clostridium difficile. Cell
cytotoxicity testing with a sensitivity of 80-90% and specificity of 99-100% is considered
the gold standard for detection of CDAD toxins, but can take up to 24 hours for detection
so is not routinely used for rapid detection in a hospital setting (Price et al, 2006).
TREATMENT
Antibiotics
The first step in treatment of Clostridium difficile is to stop using the offending
antibiotics (Oldfield, 2004). Some studies have shown that in 15-23% of CDAD
discharges discontinuing use of the offending antibiotic can relieve symptoms (Aslam et
al, 2005). In some instances changing treatment to a more effective antibiotic is
necessary to not only make the patient better but also to prevent the occurrence of
CDAD.
Metronidazole is the drug of choice when treating an infection with Clostridium
difficile (Aslam et al, 2005). Oral Vancomycin is used in place of Metronidazole when
patients fail therapy with Metronidazole, a more severe disease is encountered, or a
patient is pregnant or less than 10 years old (Modena, Gollamudi, & Friedenberg, 2006).
Metronidazole is considered the first choice to prevent further colonization of
Vancomycin resistant enterococci (VRE) (Oldfield, 2004). Bacitracin and Teicoplanin
have been used to treat CDAD, but are not considered the first line of antibiotics to treat
the disease (Oldfield, 2004; Aslam et al, 2005).
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There are antibiotics that are being studied as to their effectiveness against
Clostridium difficile. Researchers are trying to find antibiotics that are more effective at
killing Clostridium difficile and preventing the bacterium to gain resistance. Some
researchers have looked more into the effectiveness of Metronidazole (Musher et al,
2005). Other researchers have investigated giving oral antibiotics versus intravenous
antibiotics preoperatively (Wren, Ahmed, Jamal, & Safadi, 2005). The research into new
drugs has led investigators to look at two drugs called Nitazoxanide and fusidic acid
(Wullt & Odenholt, 2004; Aslam et al, 2005). This information on antibiotic usage is
presented because of the important role that antibiotics play in the prevalence of CDAD.
Alternative methods
Alternative methods have been shown to be somewhat effective in treatment of
CDAD. The methods in use include, with limited effectiveness, probiotics (introducing
helpful bacteria into the colon), immunoglobulins, and steroids (Aslam et al, 2005).
Some of the probiotics in use are yeasts, Bifid bacterium, Lactobacillus GG, L.
rhamnosus, L casei, L. plantarum, and Enterococcus faecium (SF68) (Dendukuri, Costa,
McGregor, & Brophy, 2005). Other methods in use are the use of Cholestyramine, which
binds the toxins of Clostridium difficile and inactivates those toxins (Oldfield, 2004).
Unfortunately, Cholestyramine inactivates Vancomycin when the two drugs are used
together.
PREVENTION
Cleaner hospitals
Ways to prevent the patient from contracting the disease rely on adequate
cleaning of the hospital rooms, equipment, and environment. Clostridium difficile spore
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production allows the bacteria to survive for up to 60 days in the hospital environment.
This presents a problem for housekeeping in the hospital. Appropriate agents that are
sporicidal are needed when cleaning rooms that contained previous patients with
Clostridium difficile (Wilcox et al, 2002). These agents can be tertiary ammonium,
oxygen-based, hypochlorite disinfectants, and detergent based (Wilcox et al, 2002).
Effective cleaning of hospital environments is also a topic that this study will be
unable to access efficiently. The CDC recommendations in 2003 for appropriate cleaning
agents to eradicate Clostridium difficile from the environment include meticulous
cleaning of all surfaces followed by hypochlorite based germicides as appropriate
(Schulster & Chinn, 2003). Two other groups of researchers also investigated which
cleaning agents are the most effective at reducing the amount of Clostridium difficile in
the environment and also decreasing the number of CDAD discharges. These researchers
noted varying degrees of effectiveness (Fawley, Parnell, Verity, Freeman & Wilcox,
2005; Wilcox et al, 2003). Unfortunately, current data as to what cleaning agents are
used routinely in Florida hospitals is not available. The CDC guidelines are the best
recommendations to limit the amount of bacterium that persist in the environment.
Isolation/Precautions for CDAD
The CDC isolation precaution guidelines for Clostridium difficile are to place the
patient in contact isolation for the duration of their illness (Garner, 2005). Contact
precautions include placing the patient in a private room with their own bathroom or if a
private room is not available placing them in a room with another CDAD patient. When
both of these conditions can not be met patient placement needs to be carefully
considered because of the infective nature of Clostridium difficile. Gloves should be
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worn when entering the room and the gloves should be removed before leaving the room.
Gowns should be worn if the caregiver is expected to have substantial contact with the
patient, environmental surfaces or items in the patient’s room. Remove the gown before
leaving the patient’s environment (Garner, 2005). Equipment to be used on the patient
should be limited only to the patient whenever possible. Sharing of any patient care
equipment should be done only after thorough cleaning and disinfecting of the equipment
before using on another patient (Garner, 2005). Avoidance of rectal thermometers and
cleaning the rooms of infected patients should be done with a 1:10 bleach solution
(Bartlett, 2006). Diarrhea in an adult that has a history of recent antibiotic use is also to
be considered for contact isolation so as to prevent a potential spread of Clostridium
difficile even though CDAD status has not made (Gardner, 2005).
Hand hygiene
It is worthy of note here that the CDC recommendations for hand hygiene to
prevent a patient from contracting any diseases, including CDAD. No specific
recommendations have been given for Clostridium difficile, but in 2002 the appropriate
recommendations for hand washing were given by the CDC. The first and most
important recommendation that is given is if hands are visibly soiled with blood or body
fluids (including feces) that they must be washed with soap (antibacterial or nonantibacterial) and water (Boyce and Pittet, 2002). This recommendation is a category IA
meaning it is strongly recommended and strongly supported by studies on the topic.
Other recommendations associated with CDAD are decontamination after contact with
patient’s skin (category IB), decontamination of hands after contact with blood or body
fluids when not visibly soiled (category IA), decontamination of hands after contact with
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inanimate objects in the immediate vicinity of the patient (category II), and the
decontamination of hands after removing gloves (IB) (Boyce and Pittet, 2002).
Drug therapy
Monitoring of drug therapy is another effective means of preventing Clostridium
difficile. Over medication of patients is a way to increase the prevalence of CDAD in our
hospitals. Clindamycin and the Cephalosporin family of drugs are antibiotics that appear
to cause the most problems with infection rates of Clostridium difficile (Thomas,
Stevenson, Willliamson, & Riley, 2002). Other drugs that have attributed to cause the
disease are Fluoroquinolones, Macrolides, and intravenous beta-lactam/beta-lactam
inhibitors (Pepin et al, 2005). Research into which routinely used antibiotics are causing
discharges of CDAD is well documented and has value when considering the best drug to
give patients that require treatment with antibiotics (Starr, Martin, McCoubrey, Gibson,
& Poxton, 2003; Gopal, Mahankali, and Starke, 2003). Hospitals should responsibly
monitor drug use and especially the drugs that are known to cause discharges of CDAD.
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Chapter Three: Literature Review: The rising trend of Clostridium difficile.
DISCHARGE DEFINITION AND CODING FOR CLOSTRIDIUM DIFFICILE
The coding used in this study is the International Classification of Diseases ninth
revision (ICD-9), a coding method for hospital records. Clostridium difficile, toxic
megacolon and perforated colon have their own specific ICD-9 code, and these codes are
specific for determining exact diagnoses. A patient having Clostridium difficile is defined
as any person that has tested positive for the bacteria or toxins and has documented more
than three loose stools in any given day with any of these symptoms: fever, loss of
appetite, nausea, and abdominal pain/tenderness (Oldfield, 2004; Dubberke, Reske,
McDonald, and Fraser, 2006). Established verifiable psuedomembranous colitis is also a
viable definition of the disease (CDC Clostridium difficile Information for Healthcare
providers, 2005).
REPORTING OF SUSPECTED DISCHARGES IN HOSPITAL RECORDS
A person in a hospital has a medical chart filled out by a doctor. This chart upon
discharge from the hospital is given to medical records coding personnel. These coders
take the chart and use the ICD-9 code system to appropriately assign what the discharged
patient was diagnosed with while in the hospital. Additionally, the coders are the persons
who make it possible for the hospital to bill the patient for services rendered while in the
hospital. Hospital billing relies on the coder assigning the correct ICD-9 code as an
acknowledgement of the procedures that were relied upon to treat the patient while in the
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hospital. If the coder does not do their job correctly then the patient is over or under
charged. The hospital relies on good coders to make the right decisions for accounting
and auditing purposes.
Researchers have used discharge information that rely on ICD-9 codes for correct
recognition of CDAD. These researchers have tested the validity of using this coding
system to correctly identify prevalence of CDAD. Scheurer and his colleagues attempted
to show that CDAD prevalence can be appropriately determined by using discharged
data. These researchers found that the ICD-9 codes closely approximate the true amount
of Clostridium difficile infections that were in their hospital (Scheurer, Hicks, Cook, &
Schnipper, 2006). They did note that including symptomatic patients whose test results
are readily available at time of discharge is helpful to make a more accurate assessment
of disease status (Scheurer et al, 2006). Dubberke and his colleagues also researched the
of Clostridium difficile toxin assays with ICD-9 codes attributed to discharged patients
(Dubberke et al, 2006). They found that good correlation existed between the two
sources and that large scale use of discharge diagnosis codes can be effective in
demonstrated prevalence of the disease (Dubberke et al, 2006).
CONDITIONS THAT ACCOMPANY CLOSTRIDIUM DIFFICILE
As discussed earlier there are conditions that Clostridium difficile can progress to.
These conditions are perforated colon, toxic megacolon, sepsis, and death.
Psuedomembranous colitis is not mentioned here because this condition cannot be
differentiated from Clostridium difficile during coding and the disease can occur at the
beginning of a Clostridium difficile infection. Sepsis is another condition that, using
discharge data, is difficult to differentiate from whether or not a person had sepsis before
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or after contracting Clostridium difficile. The above factors make it difficult to determine
which disease caused which condition. In consideration of these factors this study will
only list perforated colon, toxic megacolon and death as conditions that Clostridium
difficile can progress to.
GENETIC TYPES OF CLOSTRIDIUM DIFFICILE
In the past few years a large amount of research has been completed to discover
the gene structure of Clostridium difficile. In addition to the topic of toxins, the scientific
community has been searching for strains of Clostridium difficile that have been
prevalent more often than other strains. The scientific community believes that the
presence of at least one of the toxins, either A or B, is necessary for disease, with
enhanced virulence when both toxins are present (Martirosian, Szczesny, Cohen, & Silva,
2005). This is important when considering that the Center for Disease Control (CDC)
and researchers from Canada have named the strain believed to be the cause of the
majority of the new outbreaks as hyper virulent toxin type III ribotype 027 strain (Pepin
et al, 2005c). This strain has also been referred to as North American pulso-type I
(NAP1)/ribotype 027 (Louie, 2005). This strain has been implicated in a number of
outbreak settings of CDAD (Cloud & Kelly, 2007). This strain has also been shown to
produce about 15-20 times more toxin than a ‘normal strain’ of Clostridium difficile
(Louie, 2005). This strain, or a close cousin to it, has also been identified in the UK
(Pepin et al, 2005c). This strain is believed to be causing the new problems that are
present now: increased prevalence of discharges, more co-morbidities, and higher
mortality.
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EPIDEMIOLOGY
Risk factors
Clostridium difficile associated diarrhea risk factors are important to
understand and to be able to diagnose and treat hospitalized patients that may be
susceptible to contracting the disease. Six conditions that can lead to CDAD are: history
of antibiotic use, anti-neoplastic agents, age > 60 years, gastrointestinal surgery, enemas
or stool softeners, and enteric feedings, especially post pyloric (Oldfield, 2004). All of
these conditions in some way demonstrate the destruction of the normal commensal flora
that exists in normal human large and small intestines. The two most prominent risk
factors that have received the most attention are the use of antibiotics and age.
Antibiotics
Some antibiotics are more likely to cause Clostridium difficile than others, such as
Clindamycin, but even Metronidazole and Vancomycin (both of which are considered for
treatment of the disease) have been proven to be a cause of the disease (Oldfield, 2004).
A study conducted in Paris, France by Blot and his colleagues determined that
chemotherapeutic agents could cause CDAD (Blot, Escande, Besson, Barbut,Granpeix &
Asselain, 2003).
Age
The age of a patient is consistently a concern for persons infected with
Clostridium difficile. Patients >60 years old tend to have a higher prevalence rate, a
worse prognosis, and have an increased chance for relapse. There are several reasons for
these conclusions, most notably, older people are more susceptible to infections of all
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kinds, have a higher chance of being in a hospital, and a higher chance of being on
antibiotics. Pepin and his colleagues performed a study on what types of people are
considered the highest risk for having CDAD (Pepin et al, 2005a). They researched
several characteristics that could conceivably cause CDAD. They separated the years
1991-2004 in two year periods with age groups of ≤17, 18-64, and ≥65. In the early part
of this study the 18-64 age groups always seemed to have more discharges of Clostridium
difficile, but in 2003-2004 that changed drastically showing that the ≥65 age group has
over twice as many discharges as the other 2 age groups combined (Pepin et al, 2005a).
This is important because of the implications this disease has on geriatric patients. Pepin
and his colleagues also noticed that those persons ≥65 also have a significant chance of
relapse when compared to the relapse rate for the ≤17 year old age group (Pepin et al,
2005a). The published results of this study are important because drug regimens and
testing may need to be adjusted to treat the increasing number of older patients that are
contracting this infection.
The opposite end of the age spectrum is of concern as well. With a rising trend of
CDAD it is only logical to be concerned with the effect on the very young. A group of
researchers from Ontario, Canada undertook a project to determine the effectiveness of
treating infants who contracted Clostridium difficile (Tang et al, 2005). Their research
showed that the patients improved regardless of disease status or whether metronidazole
was given or not. This research demonstrates, especially in the younger age groups,
Clostridium difficile as a cause for diarrhea should not be routinely tested for, and that the
diarrhea experienced by infants is routinely from a source other than Clostridium difficile
(Tang et al, 2005).
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Studies of prevalence
Canada
Studies of the rising trend of Clostridium difficile have been ongoing because
hospitals are concerned about the nosocomial infection rates. Most reports on prevalence
of Clostridium difficile prior to 2004 discuss a small prevalence for this disease with little
threat for the disease becoming a problem. In 2004 the Canadian medical association,
discussing infection rates after 2000 reported that a high rate of Clostridium difficile is
occurring in hospitals in Montreal and 79 deaths had occurred so far (Eggertson and
Sibbald, 2004). This preliminary report lacks baseline data or any data to show exactly
how much the rates of infection have increased. The report does contain a number of
quotes from people stating that the problem will probably become worse with the
possibility that Clostridium difficile infections could become a serious problem. This
report does not show the extent of the problem but mentions that a problem may exist.
The Eggertson and Sibbald report is significant because after this report was issued, an
influx of information on just how much the disease has increased has been reported and
the seriousness of this problem persists in Canada based on the studies of other
researchers.
The increased prevalence of CDAD not only persists in Canada, but it occurs in
other parts of North America as reported by a number of researchers. Valiquette and his
colleagues note that not very good records have been kept for this disease. They
researched data accumulated during 1-½ years for discharges of Clostridium difficile
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reported for a hospital in Montreal, Canada. They found that in January of 2002 the
hospital had about 10 discharges of the disease, and in May of 2004 they had almost 40
discharges of the disease and with a high point for the disease in February of 2004 of
almost 70 discharges (Valiquette et al, 2004). The prevalence rates for this data is 2.1
discharges per 1000 admissions in 2002, 10 discharges per 1000 in 2003, and a projected
18 discharges per 1000 admissions in 2004 (Valiquette et al, 2004). This report shows
why Canada is concerned and has led Jacques Pepin and some of his colleagues to begin
a formal research study of the complexity of the Clostridium difficile problem for
Quebec, Canada.
Pepin and his colleagues researched the Canadian Clostridium difficile problem
and issued four reports that attempt to define the various factors contributing to increased
prevalence of Clostridium difficile. The first report reviewed the prevalence of CDAD
from 1991 to 2003 at the Centre Hospitalier Universetaire de Sherbrooke (CHUS). This
study is a retrospective chart review investigating details such as age, gender, CDAD
acquired place, immunosuppression, and antibiotic treatments (Pepin et al, 2004). This
hospital provided a well defined population making it possible for the researchers to
estimate population based prevalence. The prevalence of CDAD in this Canadian region
increased from 35.6 per 100,000 people in 1991 to 156.3 per 100,000 people in 2003 with
the 65 years old or higher age group increasing from 102.0 to 866.5 per 100,000 people
(Pepin et al, 2004). This study indicates that Canada has a legitimate problem with this
disease that needs addressing. The factors contributing to higher prevalence of CDAD as
indicated by the research report of Pepin et al include immunosuppression, tube feeding,
and the place acquired (hospital versus community).
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Pepin and his researchers next investigated if death rates and length of hospital
stay were significant factors for the increased prevalence of this strain of bacteria. The
following report confined the research to determine if co-morbidity contributed to the
disease and also contributed to death in a patient that had CDAD (Pepin et al, 2005c).
The database used for this study originated from records of the 687 bed tertiary hospital
in Montreal, Canada. After 365 days the study showed that on average those patients that
had been diagnosed with CDAD had a survival rate of about 65% as compared to the
control subjects' survival rate for the same time period of about 80% (Pepin et al, 2005c).
This indicates that a person who has CDAD has a higher probability of dying. Pepin and
his colleagues also completed a 30 day co-morbidity survival rate study and compared
the values to the survival rates of patients after 365 days. They reported for the 30 day
study that CDAD merely precipitated an event that could have occurred in any discharge
a few months later, but for the 365 day study, about one-sixth of the inpatients with
CDAD died (Pepin et al, 2005c). This means that a person contracting CDAD has a
higher chance of dying after one year than the group of people that are admitted to a
hospital that have no record of CDAD. Pepin and his researchers attributed most of their
infections to the NAP1/027 strain (Pepin et al, 2005c). Therefore, the survival
probabilities for this strain may not necessarily compare to other strains of Clostridium
difficile.
Some issues that have also been reported for Canada have been discussed earlier
in this paper: a) the recurrence rate for metronidazole treatment is increasing and b) the
propensity of fluoroquinolones to cause more discharges of CDAD (Pepin et al, 2005a;
Pepin et al, 2005c). Both of these reports provide adequate evidence that the prevalence
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of CDAD is increasing in Canadian hospitals. These reports provide significant factors
contributing to the rising prevalence of CDAD and offer methods that the health
community can use to reduce the rising prevalence of CDAD in our own communities.
This report by Pepin and his colleagues show that the recurrence of CDAD after
metronidazole therapy increased from 15.2% in 1991-1992 to 47.2% in 2003-2004 (Pepin
et al, 2005a). This paper contains specific data for only one hospital and it could not be
confirmed if the results of the survey apply to any other Montreal hospitals.
The November 2005 report by Pepin and his colleagues provides the most
extensive research into antibiotics and their involvement with the disease. This report
helps to visualize which drugs have the highest factors for contributing to the prevalence
of CDAD in Montreal (Pepin et al, 2005b). The results reported may not apply to other
hospitals reported by different researchers. The Pepin report also may not be useful
because the patients’ antibiotics have been separated into many groups that decreases the
population of discharges reported for each group.
One final study worthy of note that originated in Canada contains research data on
the CDAD strain that emerged in Canada, discusses the toxin production for this new
strain, and compares the prevalence of this strain compared to previous strains for this
bacterium. This new strain is labeled NAP1/027 and is the strain that was discussed
earlier in this paper. These researchers found that this strain produces 16 times more
toxin A and 23 times more toxin B than control strains (Warny et al, 2005). This greater
toxin production led these researchers to hypothesize that the new deadlier strain would
increase the prevalence of CDAD. Intuitively this makes sense because an increase in
toxin production would increase the prevalence of CDAD. A problem with this report is
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that the report compares 15 NAP1/027 strains with 25 toxinotype 0 strains (Warny et al,
2005). The report did not appear to have a high number of discharges and this lowers the
significance of the report. The culture and growth curve analysis results have been
questioned by a group of researchers (Freeman, Fawley, Baines, & Wilcox, 2006).
Freeman and her colleagues refute the methods to reproduce growth in vivo with in vitro
analysis are not sound enough to give accurate results. The researchers did study the
strains from the same geographical areas as the NAP1/027 strains so that geography
could not be a factor that confounded the study (Freeman et al, 2006). The report by
Warny and his colleagues does a good job of showing reasons why Clostridium difficile
is starting to cause problems in other regions of the world, but the numbers for amount of
toxin may be lower than reported by this research (Warny et al, 2005).
United States
Research results from Canada hospitals concerning Clostridium difficile
prevalence may be important for US hospitals because Canada is a close neighbor.
Valiquette et al researched the Clostridium difficile rates for Canada, and other areas of
the world to demonstrate that the disease is also increasing in other parts of the world
(Valiquette et al, 2004). These researchers used data from Oregon, Pittsburgh, and the
US national nosocomial surveillance database. These three respective places all
experienced some type of increase whether it was in CDAD prevalence or in mortality
rates (Valiquette et al, 2004). More research into the disease in the United States needs to
be done to determine the extent of the problem.
A study was completed by Clifford McDonald and his colleagues. These
researchers used the National hospital discharge survey information records to conduct
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their research. This study is one of the most comprehensive and thorough medical record
studies performed on the topic of Clostridium difficile (McDonald et al, 2006).
McDonald’s report is significant because it defines that the prevalence rates for
Clostridium difficile are increasing in the US. McDonald et al shows that the prevalence
of Clostridium difficile increased from 31/100,000 people in 1996 to 61/100,000 people
in 2003 (McDonald et al, 2006). This report notes that the increased prevalence in the
≥65 year age group is disproportionately higher at 228/100,000 people as compared to the
next younger age group, 45-64 year old, that had a prevalence of 40/100,000 people
(McDonald et al, 2006). Another item of note is that this article also observed higher
prevalence rates across the entire US with the northeast region of the US having the
highest prevalence rates. It is interesting to note the South region, including Florida, has
a prevalence rate of about 20 Clostridium difficile positive patient discharges per 100,000
people in 1996. This rate increased to just over 40 Clostridium difficile positive
discharges per 100,000 people in 2003 (McDonald et al, 2006). This report demonstrates
that the prevalence rates of CDAD are increasing in the US and also increasing in the
south region of the US.
A previous study done at a statewide level was performed in Oregon (Chandler,
Hedberg, & Cieslak, 2007). The prevalence of CDAD in Oregon increased from 1.4 to
3.3 discharges per 1,000 discharged patients from 1995 to 2002 (Chandler et al, 2007).
These researchers were unable to find any notable changes in hospital practices that could
have perpetuated the rise in prevalence. This reports use of a descriptive study is close in
method type to the study that is being researched in this paper for the state of Florida.

28

United Kingdom
The United Kingdom, similar to U.S. and Canada, has also been experiencing a
rise in prevalence rates of Clostridium difficile accompanied with a rise in death rates
(Brierley, 2005). Rob Brierley discusses specifically the number of deaths was at 25
across 15 hospitals, but does not provide baseline information for CDAD prevalence in
UK. Brierley does refer to some preliminary typing of some of the discharges that
occurred at the Stoke Mandeville hospital, where the CDAD epidemic was believed to
have begun. The preliminary typing indicates that the ribotype 027 strain has at least
partial blame for the outbreak in the UK (Brierley, 2005). Valiquette and his colleagues
report using information gleaned from the UK health protection agency communicable
disease centre (Valiquette et al, 2004). This report shows that in 1986/87 the hospitals
had <2000 discharges of Clostridium difficile as compared to >12,000 discharges in
2000/01 (Valiquette et al, 2004). This report demonstrates that the problem with this
disease is not confined to Canada, but other parts of the world are experiencing the same
Clostridium difficile problem.
Pepin and his colleagues also note that CDAD prevalence is increasing in the UK
and that further research is needed to control these increases. They report that the
prevalence of CDAD has doubled from 2001 to 2004 (Pepin et al, 2005a). The report
contains preliminary information that ribotype 027 strain has spread to some areas of the
U.K. and has contributed to the increased prevalence of CDAD for this country.
The previous articles discuss ribotype 027 strain typing to show that this strain in
England is similar to the one observed in North America. Research by Warren Fawley
and his colleagues included identifying the important subtypes of the disease in Leeds,
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United Kingdom (Fawley et al, 2005). Fawley’s results showed on ward A that 95.2% of
the Clostridium difficile infections were attributed to the PCR ribotype Ia, and in the
other ward researched, ward B, the ribotype causing 97.5% of the discharges was type
PCR ribotype Ia (Fawley et al, 2005). PCR ribotype Ia is similar to the NAP1/027 strain
that has been identified in North America. Fawley also discusses that this strain seems to
be thriving and growing and is becoming the more predominant strain in other parts of
the U.K. as well.
Other countries
Warren Fawley’s typing of Clostridium difficile strains led him to report some
instances of PCR type Ia, commonly referred to as ribotype 1, in Belgium and France
(Fawley et al, 2005). An outbreak of CDAD was noted in Paris, France in 1996, but a
specific strain of the bacteria was not identified as the culprit (Blot et al, 2003). This
study attempted to define why Clostridium difficile is causing infections among
chemotherapy patients. This report provides some evidence that outbreaks of this disease
are occurring outside of the U.S., U.K., and Canada.
Norwegian researchers reported on Clostridium difficile infections observed in
two university hospitals in Oslo, Norway. These researchers attempted to discover the
extent of the infections caused by this bacterium by examining risk factors that may
contribute to the increased prevalence of CDAD (Berild et al, 2003). The report focused
on reasons for the disease outbreaks in their facilities. Berild and colleagues discuss
prevalence of CDAD in two hospitals. In 1993 one hospital reported a prevalence of
about 4 discharges of CDAD per 100,000 people as compared to that same hospital
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having a prevalence of about 17 discharges of CDAD per 100,000 people in 2001 (Berild
et al, 2003).
Sweden is another country reporting mortality rates caused by CDAD. Torbjorn Noren
reports that the mortality rate for Clostridium difficile from a PCR ribotype 17 strain
(serogroup C) was as high as 13% in the year 2000 (Noren, 2005). Noren’s report
attempts to confirm that in Orebro county, Sweden the mortality rate is similar to rates
reported by Canadian researchers. Noren’s report shows that high mortality rates are not
confined to only North America but that other countries are experiencing strains of
deadly Clostridium difficile infections.
STUDIES TO PREVENT THE INCREASING PREVALENCE OF CDAD
The rising trend of CDAD is apparent and methods are needed to prevent the
increased prevalence of this disease. Thomas J. Louie makes some suggestions based on
various articles he has researched (Louie, 2005). His suggestions are reduction in
patients in crowded wards, lower toilet to bed ratios, and increased infection control
methods in hospitals to treat CDAD infections (Louie, 2005). These suggestions are
given repeatedly by other researchers and are not new. One problem with these
suggestions is that they require hospital funds to make the necessary changes. Therefore,
research that identifies less expensive methods for preventing the prevalence of CDAD
and growth of the bacteria are important.
One of the factors noted by researchers that can reduce Clostridium difficile
infection rates is modifying the antibiotics given in hospital wards. In Western Australia
Thomas and her colleagues accumulated data as they made efforts to curtail the
prevalence of Clostridium difficile in their hospital (Thomas et al, 2002). These
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researchers noted that the prevalence of Clostridium difficile has been increasing
gradually at their hospital and methods were used to modify antibiotic usage in an
attempt to curtail the increasing infection rates (Thomas et al, 2002). This hospital
almost completely abolished the use of third-generation cephalosporins by the year 2000
in an effort to prevent further growth of the bacteria. This method decreased the
prevalence from almost 3 discharges of CDAD per 1000 patients in 1993 to below 1
discharge of CDAD per 1000 patients in 2000. The other statistic of note is that by 2000,
the amount of CDAD per occupied bed days (20 patients per 100,000 bed days) was at
the lowest rate in this hospital since 1983 (Thomas et al, 2002). This is convincing
research that using antibiotics appropriately can aid in lowering infection rates for
CDAD. This report fails to record the alternative drugs used to treat patients. If the
alternative drugs used in this hospital were Metronidazole and Vancomycin, then the data
seems reasonable because Metronidazole and Vancomycin are drugs that have been used
successfully to treat CDAD. The report contains a note that they used Clindamycin on a
very limited level, which means that Clindamycin was not the drug of choice to replace
the use of third-generation Cephalosporins. The amount of people in the study was high
providing confidence that the values given are statistically significant.
A report by Vesta and colleagues attempted to show that no specific drug is
responsible for discharges of CDAD (Vesta, Wells, Gentry, & Stipek, 2005). This
research, although it had good intentions, did not have enough data points to be
statistically significant. The report contained data for only 144 patients and separating
the data into 9 drug categories reduced the statistical significance of the report too low to
be comfortable with the conclusions. As discussed earlier, Pepin and his colleagues did
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show that Floroquinolones, all Cephalosporins, Macrolides, and Clindamycin were
factors affecting higher prevalence of Clostridium difficile in Quebec hospitals (Pepin et
al, 2005b). This report used a database containing 7421 discharges of CDAD. The Pepin
et al report concludes that the drugs studied do increase prevalence of CDAD in hospitals
(Pepin et al, 2005b).
A previous paragraph noted that research studies reported on the efficacy of
Metronidazole and Vancomycin in treating the newly emerging strains of Clostridium
difficile (Freeman, Stott, Baines, Fawley, & Wilcox, 2005b). At Leeds, U.K. the
resistance of Clostridium difficile bacteria to Vancomycin and Metronidazole remains
small according to their research. Another effort to find new and more efficient drugs
was undertaken by Jane Freeman and her colleagues. This report discusses the
effectiveness of Ramoplanin compared to vancomycin in treating CDAD (Freeman,
Baines, Jabes, & Wilcox, 2005a). This report uses hamsters and models treatment by
randomizing injections into hamsters for CDAD treatment with either Ramoplanin or
Vancomycin. This report showed that, while Vancomycin reduced the amount of
bacteria in the intestines during treatment, Ramoplanin reduced both the amount of
bacteria and the amount of spores, which Vancomycin failed to do (Freeman et al,
2005a). This suggests that ramoplanin could be a good alternative to Vancomycin. No
reports on the effectiveness in humans were found. The research on hamsters is
convincing, but further studies into the effectiveness for humans needs to be shown.
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Chapter Four: Methods
STUDY DESIGN
This thesis is a descriptive cross-sectional study for the years 1998 thru 2004 to
determine the prevalence of Clostridium difficile in Florida’s acute care hospitals.
Hospital discharge data was analyzed to compare the prevalence, length of hospital stay,
age, race, gender, and mortality over time for CDAD positive patients to determine if the
values are changes from year to year. The data analysis also compared the mortality rates
for CDAD positive patients to those patients that have no record of the disease.
STUDY POPULATION
The study population is persons discharged from Florida’s hospitals not including
persons admitted to military hospitals. This data set contains all hospital discharges from
Florida’s non-federal hospitals regardless of where the patients’ primary residence is.
INCLUSION CRITERIA
A discharged patient is considered to have CDAD when the primary or secondary
diagnosis ICD-9 code is 00845. The discharge information from 1998 through 2004 is
included in this study. The year that a person is discharged from the hospital is the year
that that person is included in the data base.
EXCLUSION CRITERIA
This data set only contains information from Florida’s non federal hospitals. Data
from other states or countries, nursing homes in Florida, and federal hospitals (military
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and Veteran’s Association) in Florida are excluded. Patients with CDAD and are not
admitted to a hospital are also not included in this data set. Hospital discharge data
before 1998 and after 2004 are not included in this study.
DATA SOURCES
This study analyses data from the Agency for Healthcare Administration
(AHCA). The AHCA discharge data used in this study contains hospital discharges for
all non-federal hospitals in the state of Florida. This data, with permission of the Florida
Department of Health, is being used in this study to examine the effects of Clostridium
difficile on people being admitted to Florida’s acute care hospitals.
DATA MANAGEMENT
The large amount of information provided by this data required some preparation
to make it usable for the purposes of this study. The biostatistical software in use for this
study is Statistical Analysis Software (SAS) version 8.1 or higher. The data was
provided by year in separate SAS files. There are at least 31 different categories of
information. This information has been provided with no personal identifiers so no
confidentiality has been breached. The discharge information was provided in one-year
increments. There are some minor differences in the names for categories during some
years, and these differences have been changed so that the information could be
combined into one main dataset that contains all information from 1998-2004. Important
categories used in this study are year of discharge, discharge status, length of hospital
stay, gross charges, gender, principal diagnoses code, secondary diagnoses code, patient
age at admission, and patient race.
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The information has been compiled on a yearly basis to determine the change
over time for CDAD. The prevalence of CDAD has been determined by examining both
the principal diagnosis codes and secondary diagnosis codes to establish if the patient
was given the ICD-9 code of ‘00845’. The discharges of CDAD have been extracted
from the ACHA data so that details of patients who have been diagnosed with the disease
can be analyzed. After the group of Clostridium difficile patients was extracted from the
main data, the group was then compared to the remaining non-CDAD patients group to
determine prevalence of CDAD. The comparison of Clostridium difficile positive patient
population to the non-diseased hospital patient population was done for each year (1998
through 2004) to determine if there are any differences.
Along with determining CDAD prevalence, the next major variable of interest is
discharge status. Discharge status is important because this is the primary method for
determining if a patient expired while in the hospital. The information provided in the
data that explains discharge status was changed from the 10-11 discharge categories to
two discharge categories, whether or not the discharged patient was alive or dead when
they left the hospital. These changes allowed this study to determine the death
prevalence rates for Clostridium difficile positive patients. Changes to the discharge
status were performed for both the Clostridium difficile positive population and for the
non-Clostridium difficile positive population. Death as an outcome is not only important
to establish for all patients, but also for all patients that are positive for Clostridium
difficile.
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DEFINITION OF VARIABLES
Variables are explained in these paragraphs providing an understanding for
interpreting the results of the data analysis. The length of hospital stay is determined by
subtracting the date a person was discharged from the hospital from the time at which
they entered the hospital. If a person is discharged from the hospital and then readmitted
to the hospital at some later time after they have been discharged this event would be
considered a new admission and the length of hospital stay would start over with the new
admission regardless of what reason the new admission is for. Cost per patient is
provided in the data and represents the total dollars charged to the patient.
A patient’s gender is given as male, female or other in the ACHA data. The race
group is divided into 3 categories: white, black and other. The other category includes
persons from races that include American Indian/Eskimo/Aleut, Asian or Pacific Islander,
White Hispanic, Black Hispanic, and other.
As discussed previously, Clostridium difficile is given an ICD-9 code of 00845.
Other conditions of note for this study are toxic megacolon and perforated colon. These
conditions are coded as 556.9 and 569.83 respectively (Hart and Hopkins, 2004). These
two conditions are discussed as they pertain to persons who have Clostridium difficile.
DATA ANAYLSIS
This data has been analyzed on a year-by-year basis to more fully understand the
effect that Clostridium difficile has had on the Florida hospital population. Starting with
the year 1998, the data has been manipulated to estimate means and sequencing
operations was performed to define if the variables important to this study are present.
Values computed for this study include percent female, percent non-white, mortality,
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total patients per year that were diagnosed with Clostridium difficile, mean age of
population per year, average length of hospital stay per year, and total gross charges per
patient per year. These values were then compared to the same values estimated for the
Clostridium difficile positive group. The values were used to compare the Clostridium
difficile positive population with the full discharged patient population for each year.
The values for mortality among the CDAD patients were compared to the mortality for
patients that did not have CDAD.
To expand the discussion about ages the data was divided into 11 age groups.
The data was divided into 11 age groups to provide a better understanding concerning the
role age plays in the disease process. The 11 age groups are ≤ 1, > 1-10, >10-20, >20-30,
>30-40, >40-50, >50-60, >60-70, >70-80, >80-90, and >90. These age groups were then
compared on a year by year basis to consider if changes in average length of hospital
stay, prevalence, mortality rates, race distribution and gender percentages occurred over
the years of the study.
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Chapter Five: Results
STUDY POPULATION CHARACTERISTICS
Age
An analysis of the AHCA data yielded the following results: The median age for
the non-CDAD patients discharged from Florida hospitals decreased from 56 in 1998 to
55 in 2004. The Clostridium difficile positive patients increased slightly from a median
age of 74 in 1998 to a median age of 75 in 2004 (See appendix A). The percentage of
persons with CDAD that are >60 years old is 74.7% in 1998 and 76.8% in 2004 (see
appendix B). These numbers are much higher than the percentage of persons without
CDAD that are > 60 years old [45.8% in 1998 and 43.6 % in 2004] (see appendix B).
Table 1: Population of Florida, total number of acute care hospital discharges and the
median ages of both the CDAD and non-CDAD groups of discharged patients for the
years 1998-2004
Variables

Year

Population of
Florida (millions)
Total discharges
Ages (in years)
Median for nonCDAD
Median CDAD

1998

1999

2000

2001

2002

2003

2004

15.310
2.098

15.680
2.155

16.075
2.242

16.412
2.341

16.772
2.382

17.164
2.444

17.613
2.491

56
74

56
74

56
74

56
75

55
75

55
75

55
75

Gender
The percentage of females in 1998 for the non-CDAD patient discharge
population is 56.97% compared to 56.74% in 2004 (see table 2). The percentage of
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females for the CDAD population group differs slightly from the non-CDAD group with
1998 having 57.98 % female as compared to 2004 CDAD patients having 58.67%
female. The gender distribution will be discussed, in reference to age group stratification,
later in this chapter.
Table 2: The gender distribution of the CDAD and non-CDAD Florida acute care
hospital patient groups for the years 1998-2004.
Variables Year
Gender
Non-CDAD male,
(millions)
Non-CDAD
female, (millions)
Non-CDAD
percent Female
CDAD male
CDAD female
CDAD percent
female

1998

1999

2000

2001

2002

2003

2004

.900

.926

.957

1.001

1.017

1.044

1.069

1.191

1.221

1.276

1.331

1.354

1.383

1.402

56.96
3,004
4,145

56.86
3,152
4,424

57.13
3,330
4,521

57.08
4,561
6,419

57.11
6,184
8,436

57.00
7,250
9,903

56.75
8,349
11,852

57.98

58.39

57.58

58.46

57.70

57.73

58.67

Racial distribution
Race distribution was analyzed using the factor percent non-white. The data was
separated into 8 racial classes including no response to the question and a category named
other. The percent non-white grouping was used to analyze the data for patients who
enter Florida hospitals. The non-CDAD patient population of Florida has a racial
distribution of 29.33 percent non-white in 1998 and 33.79 percent non-white in 2004 (see
Table 3). For the Clostridium difficile positive patients the percent non-white is 18.17 in
1998 and 21.03 in 2004 (see Table 3).
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Table 3: The racial distribution of the CDAD and non-CDAD Florida acute care hospital
patient groups for the years 1998-2004.
Variables Year
Race
Non-CDAD white,
(millions)
Non-CDAD black,
(millions)
Non-CDAD other,
(millions)
Percent non-white
CDAD white
CDAD black
CDAD other
Percent non-white

1998

1999

2000

2001

2002

2003

2004

1.477

1.495

1.552

1.602

1.608

1.627

1.636

.300

.304

.326

.342

.350

.366

.386

.313
29.33
5,850
617
682
18.17

.348
30.27
5,976
643
957
21.12

.356
30.52
6,189
774
888
21.17

.387
31.23
8,795
995
1,190
19.90

.409
31.92
11,770
1,388
1,462
19.49

.433
32.94
13,870
1,635
1,648
19.13

.448
33.79
15,953
2,154
2,094
21.03

Length of hospital stay
Length of hospital stay for Clostridium difficile positive patients is one of the
largest differences between CDAD and non-CDAD patient populations. In 1998 the nonCDAD patient population average length of hospital stay was 4.94 days compared to
13.47 days for CDAD patients. In 2004 the average hospital stay for non-CDAD patients
was 4.88 days and the average hospital stay for CDAD patients was 13.07 days (see table
4).
Table 4: The average length of stay in the hospital for CDAD and non-CDAD Florida
acute care hospital patients for the years 1998-2004.
Variables Year
Length of hospital stay
(days)
Mean non-CDAD
Mean CDAD

1998

1999

2000

2001

2002

2003

2004

4.94
13.47

4.93
13.35

4.85
13.86

4.82
13.99

4.85
13.77

4.86
13.28

4.88
13.07

In addition to average hospital stay for the total CDAD and non-CDAD patient
populations, this study determined the average length of hospital stay for 11 age groups.
The age groups showing the greatest difference between the non-CDAD group and those
patients with CDAD are the age groups ≤ 1, >10-20, and >50-60 (see Appendix E).
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Cost per patient
The non-CDAD average patient cost increased from $14,401 total charges per
patient in 1998 to $25,561 per patient in 2004. These values are much smaller than the
patients who contracted CDAD in Florida’s hospitals [$40,773 in 1998 and $63,003 in
2004, respectively] (see table 6 and appendix F). If you multiply the number of persons
that had CDAD in 2004 times the additional days in the hospital, the total charge is over
750 million dollars greater than for the non-CDAD patients.

Table 6: The total cost per discharge for CDAD and non-CDAD Florida acute care
hospital patients for the years 1998-2004.
Variables Year
Total charges per
discharge
Mean non-CDAD
Mean CDAD
positive

1998

1999

2000

2001

2002

2003

2004

14,401

15,459

16,756

18,472

21,204

23,549

25,561

40,773

42,983

48,179

51,287

57,603

61,047

63,003

Co-morbidities
Perforated colon affected 27 Clostridium difficile positive patients in 1998 and 56
in 2004 (see appendix G). The rate of perforated colon per 1,000 CDAD positive
discharged patients is 3.78 in 1998 and 2.77 in 2004 (see appendix H). Toxic megacolon
occurred in a higher number of CDAD patients, 44 in 1998 and 92 in 2004 (see appendix
G). The rate of toxic megacolon per 1,000 CDAD positive patients is 6.15 in 1998 and
4.55 in 2004 (see appendix H).
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CHANGES OF INTEREST IN POPULATION OVER TIME
Discharges
The total number of Clostridium difficile positive patients from 1998 to 2004
was 7,149 to 20,201 (see Appendix I). The number of discharges of CDAD per 1,000
discharged patients is 3.40 in 1998 and 8.11 in 2004. Figure 10 shows that the
prevalence of CDAD per 1,000 hospital patients continues to increase during the seven
years of this study (see Appendix J). The total number of discharges in 2001 rose sharply
to 10,980 as compared to 7,851 discharges in 2000. This rise in CDAD is also reflected
by the rate per 1,000 patients which rose from 3.50 in 2000 to 4.69 in 2001. This number
is important because CDAD prevalence was relatively constant before 2001. The
research presented in this study also shows that in 2003 Florida had a rate of 99.9
discharges per 100,000 population of Florida (see appendix K).
Table 7: The number of CDAD positive discharges and CDAD discharges per 1,000
Florida hospital acute care discharged patients for the years 1998-2004.
Variables

Year

Population of
Florida, (millions)
Total discharges,
millions
CDAD positive
discharges
Total CDAD
discharges per
1000 patients

1998

1999

2000

2001

2002

2003

2004

15.310

15.680

16.075

16.412

16.772

17.164

17.613

2.098

2.154

2.242

2.341

2.382

2.444

2.491

7,149

7,576

7,851

10,980

14,620

17,153

20,201

3.40

3.51

3.50

4.69

6.13

7.02

8.11

This study also divides the patients in 11 age groups to determine the effect of
CDAD on the groups. Figures 11 and 12 demonstrate that not only is the amount of
CDAD discharges increasing in Florida, but the prevalence is also increasing (see
appendices L and M). One example is the >80-90 age group. In 1998 the number of
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CDAD discharges was 1735 and in 2004 the number of CDAD discharges increased to
5483 (see Appendix L). The CDAD prevalence per 1,000 discharged patients in the >8090 age group is 6.95 in 1998 and 18.40 in 2004 (see Appendix M).
Gender for discharges in the individual age groups
The prevalence of CDAD discharges for gender and racial groups for 1998
through 2004 is shown in Appendices N thru S. Florida’s discharge data was separated
into male and female groups with three racial groups, white, black and other races.
Generally the female gender in the three racial groups demonstrates a greater prevalence
difference when comparing the >1-10 age group to the >10-20 age group than the male
gender of the same race. White females have the highest prevalence of all the gender
groups (see appendix O). The ‘other’ male gender has the lowest prevalence in the older
age groups (see appendix R).
Racial distribution for the age groups
Race was also investigated in this study to determine if race is an important
factor. Prevalence in the white race group had the highest numbers for both male and
female genders at 18.1 discharges per 1,000 white male >80-90 year old patients for 2004
and 21.2 discharges per 1,000 white female >80-90 year old patients in 2004 (see
appendix N and O). The lowest prevalence for the >80-90 year old group was in the
‘other’ racial groups with 12.1 discharges per 1,000 other male patients in 2004 and 12.6
discharges per 1,000 other female patients in 2004 for that age group, gender, and race.
Length of hospital stay
The biggest change in length of hospital stay occurred in the ≤ 1 age group with a
1998 average length of stay of 12.31 days for a patient with CDAD and in 2004 that
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value increased to 17.85 days (see table 2). Also note in table 2 that the largest difference
in length of days stayed in the hospital for non-CDAD patients compared to CDAD
patients is for the ≤ 1 age group. Note in the >90 age group that the CDAD patients in
1998 had an average length of hospital stay of 11.60 days and in 2004 the value is 9.67
days.
Deaths
The number of deaths for persons with CDAD was 678 in 1998, 735 in 1999, 761
in 2000, 1,144 in 2001, 1,575 in 2002, 1,831 in 2003 and 2,043 in 2004. The percent
mortality for the CDAD positive and CDAD negative patients is shown in figure 17 (see
appendix R). The percent mortality for the CDAD positive patients versus CDAD
negative patients increases by over a point when comparing 2004 to 1998 (4.64 and 3.57
respectively).
This study investigated not only the mortality rate for each individual year, but
also mortality rates for each age group per year. Figure 19, appendix T, shows the
percent mortality for the 11 age groups. The mortality percent and the mortality per
10,000 discharged hospitalized patients is shown in Tables 8 and 9 (appendices W and
X), respectively. The mortality of CDAD patients per 10,000 discharged patients for the
>80-90 age group increased from 8.41 CDAD deaths in 1998 to 23.9 CDAD deaths in
2004. The >90 age group also had an increased death rate per 10,000 discharged patients
of 10.4 CDAD deaths in 1998 to 32.6 CDAD deaths in 2004 (see Table 9, appendix X).
Total numbers of discharges and deaths for the individual age groups and years is listed
in tables 10, 11, and 12 (see appendices Y, Z, and AA respectively).
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Chapter Six: Discussion
LIMITATIONS OF THE STUDY
The following are limitations when using large amounts of patient discharged
data. The AHCA data does not identify someone that has multiple admissions to a
hospital in the same year. This is a concern because a patient may have multiple
admissions with Clostridium difficile infections in the same year. The recurrence rate of
CDAD can be as low as 5% or as high as 20-25% (Pepin et al, 2005a; Schroeder, 2005).
Authors’ opinions vary on this topic and recurrence rates for Florida are unknown. Other
limitations include non-specific use of diagnose codes, transcription errors of those
persons entering the data, and inaccurate diagnoses of patient’s disease.
The discharge data does not indicate the time at which a person contracted
CDAD. Therefore, the length of hospital stay includes both the time a person was in the
hospital before they contracted CDAD and the time they were in the hospital during
recovery from CDAD. In summary, although the above five limitations do exist, these
limitations are minor when compared to the information gleaned from the data and do not
detract from the conclusions of this study.
STRENGTHS OF THE STUDY
Other than the pharmacy data, cleaning solvent, and background knowledge of
certain patients, the AHCA data is complete and is the best available information for this
large population. This data, although there could be missing information, is capable of
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providing adequate information to perform the analysis and determine prevalence rates of
Clostridium difficile in Florida hospitals.
A report by Peter Layde and his colleagues (Layde, et al, 2004) discusses the use
of data sets similar to the AHCA data with the intent of showing the usefulness of these
data sets. Layde et al, 2004 performed an analysis studying medical injury using hospital
discharge data. Their results using validation studies shows relatively high specificity and
sensitivity when comparing hospital discharge datasets to medical record reviews. No
mention was made of the sensitivity and specificity actual values, but ICD-9 codes were
used to determine medical injury. This method of verifying medical injury is similar to
the method that is used to determine Clostridium difficile infection rates in this study.
The Layde report (Layde et al, 2004) supports the conclusion that using AHCA data is an
effective tool for obtaining prevalence for Clostridium difficile.
A pilot study using hospital discharge data to access the morbidity of Rotavirus
was completed and this report also demonstrates the usefulness of statewide discharge
data (Parashar, Chung, Holman, Ryder, Hadler, and Glass, 1999). The Parashar et al
report, using the Connecticut statewide discharge hospital database, shows that 10.4% of
all diarrhea associated hospitalizations were attributed to Rotavirus. This value nearly
matches the nationally reported values for the Northeast region of the U.S. (Parashar et
al, 1999200). Parashar and his colleague’s show that using statewide discharge data
provides a useful tool for a research project and can be effective in measuring trends for
disease in some states. The above two studies demonstrate that using information from
hospital discharge data, although there may be a few limitations, provides a useful tool
for tracking and monitoring of diseases at a statewide level.
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A study that discusses Clostridium difficile more specifically discusses the
effectiveness of using ICD-9 codes to correctly determine the amount of CDAD that is
present in hospitals. Dubberke and his colleagues show that good correlation existed
between Clostridium difficile toxin assay and ICD-9 code determination of the disease
(Dubberke et al, 2006). This is important when considering the information provided in
the AHCA hospital discharge data. The information provided in this study relies solely
on the correct assignment of the ICD-9 code to CDAD to make an assessment of the
persons that have the disease. The report by Dubberke (Dubberke et al, 2006) provides
good evidence that using ICD-9 codes to determine disease status, especially in the
discharge of Clostridium difficile, can be accurate and helpful to determine disease
prevalence.
INTERPRETATIONS OF RESULTS
Characteristics of the study population
This study shows patients discharged from Florida hospitals have an increasing
trend for contracting Clostridium difficile. The results of this study show that the number
of discharged patients contracting Clostridium difficile has increased by more than 10,000
discharges when comparing 2004 to 1998. The disease rate per 1,000 patients showed
almost a 2.5 times higher rate in 2004 than in 1998. The prevalence of CDAD change
from 2000 to 2001 supports the theory that a new more highly virulent strain of the
bacteria began to infect Florida patients in that year (see Appendix J). C. McDonald and
his colleagues established a rate of 45 discharges per 100,000 U.S. population in the
southern region of the United States for the year 2003 and the national average was
established by McDonald as 61 per 100,000 U.S. population (McDonald et al, 2006).
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These numbers are in contrast to the rate presented here which is 99.9 discharges per
100,000 population in Florida for the year 2003. These numbers show that CDAD is a
significant patient problem in Florida’s acute care hospitals.
Age
Age is one of the most important factors with influence on the percentage of
patients that become infected with Clostridium difficile. Figure 2 demonstrates the
importance of this factor by showing that over 70% of the CDAD positive patients are
over 60 years old compared to the non-CDAD population that is under 50% (Appendix
B). Our analysis demonstrates that older people have a higher prevalence of CDAD.
Dividing the population into 11 age groups shows the effects of CDAD among different
age groups in the population.
Age stratification
McDonald and his colleagues used 4 different age group categories to show how
CDAD affects different aged individuals (McDonald et al, 2006). This study
demonstrates, for CDAD infection rates, that as a person becomes older their chances
increase dramatically for contracting CDAD. The other conclusion from this study is that
during the years of the study CDAD prevalence has increased in all age groups (see
Appendix M). This is especially evident among the older age groups.

Another

significant finding in this study occurs in the >1-10 age group. The CDAD prevalence
per 1,000 patients shows a fairly constant increase among the age groups as they become
older, but the >1-10 age group is almost twice as high as the next age group, >10-20. The
>1-10 age group partially follows the pattern of the >30-40 age group which is 2 more
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age groups ahead of it. In attempt to explain this we did gender and racial distributions to
discuss this interesting phenomenon.
Length of hospital stay and cost per patient
This study shows that a new more virulent Clostridium difficile bacteria strain
may be a good explanation for increasing prevalence of this disease. Length of hospital
stay and total charges at patient discharge are also factors that may support the conclusion
of this study. The increasing patient total costs may be enough incentive to motivate
researchers to provide more time and resources to patients that have been diagnosed with
CDAD in Florida hospitals. This study demonstrates that discharged patients who have
contracted Clostridium difficile are in hospitals an average of 9 days longer than patients
with no evidence of CDAD at a total increased cost of over $35,000 per patient. The
additional dollars equates to over 750 million spent to treat this disease in 2004 as
compared to what would have been spent if no patients contracted Clostridium difficile.
The ≤ 1 age group is puzzling especially when you view the change in average
length of hospital stay for the CDAD patients for 1998 and 2004. The over 5 more days
that 2004 patients spend in the hospital for this age group is not easy to explain. The
non-CDAD group does not seem to exhibit much of any change for the age groups from
the year 1998-2004. The other major difference seen in Table 5 is the >90 year old age
group CDAD population average length of hospital stay change from the year 1998 to
2004. This number decreased by almost 2 days. It is not known if hospitals are able to
diagnose these problems quicker, antibiotics are given in a better dosage so as to work
faster, or these patients are being discharged to a geriatric facility were they can be
treated and monitored more closely.
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Gender
Although no previous published reports on Clostridium difficile have mentioned
gender or race as a cause for this disease this study shows the distribution of gender and
race for each age group as shown in Appendices N through S. Notice in almost all of
these appendices a higher prevalence for CDAD females in all three of the racial groups.
In 2003 the prevalence of CDAD female discharges for the >1-10 age group is over four
times higher than the >10-20 age group for 2003 (see Appendix S). Two reasons for the
higher female prevalence may be the lower prevalence for the >10-20 age group and the
other may be the higher prevalence for the female gender when compared to the male
gender of the same race (see appendices N thru S). This higher prevalence is difficult to
explain using the discharge data and more research into these differences is needed. The
older age groups show a consistent pattern for both gender and race groups with a higher
prevalence for CDAD in the age groups over 50 years old.
Racial distribution
The race with the highest prevalence is white (see appendix N and O). Generally,
the races tend to have a prevalence that is higher as a person is older. The prevalence is
relatively constant when comparing the different races to each other. Except for the spike
in the >80-90 age group prevalence for the black female group (Appendix O), black male,
other male, and other female have nearly the same prevalence with the other racial group
having a slightly lower prevalence than the black CDAD group (see appendix P thru S).
Another difference is the lower CDAD prevalence shown in the female black group and
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other race group >10-20 age group. These groups tend to have one half to one third the
prevalence when compared to the prevalence for the other gender racial groups (see
Appendix Q and S). Race at least in Florida does not seem to be a contributor to the rise
in discharges for the CDAD disease.
Death rate information
The mortality rate for Clostridium difficile positive patients when compared to the
mortality rate for patients who did not have the disease shows some interesting figures.
Generally speaking the majority of the age groups in this study showed decreasing
mortality rates for the patients who did not contract CDAD. This is in contrast to the
CDAD positive patients who generally had a relatively constant mortality with the age
groups that are >70 having increasing mortality. This information is consistent with
reported increasing death rates observed in Canada, the United States, and the United
Kingdom.
This study also shows that older patients are more susceptible to contract the
disease and die. The data analysis shows that death rates for age groups that >70 years
old have mortality rates over 10%. This percentage is in contrast to the mortality rate of
lower than 7% among patients in the same age groups who did not have Clostridium
difficile. When considering the change in mortality rates, of CDAD positive patients,
over the years of this study, the >90 age group does show an increasing trend. This is in
contrast to the decreasing mortality rate for patients in the same age group that do not
contract CDAD.
A theory advocated at the beginning of this study was that a more virulent strain
of Clostridium difficile would affect all age groups, not just the >60 age group. This is
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the discharge for the >30-40 age group where the mortality rate increases from 2.89% in
1998 to 4.10% in 2004 (see appendix W). For the >50-60 age group this is not the case
because the mortality rate decreases from 8.89% in 1998 to 6.41% in 2004 (see appendix
W). The mortality rate is higher for Clostridium difficile positive individuals, but the
rates don’t appear to be increasing for all age groups. Younger patients are dying with
this disease, but do not appear, generally, to have a consistently increasing mortality rate
over the years of this study. The increase in CDAD discharges leads to a higher number
of deaths per 10,000 discharged patients by age group as shown in Table 9. The mortality
percent in the >50-60 age group (Table 8) shows a slight decrease for the years of this
study while the CDAD deaths per 10,000 discharged patients (Table 9) shows an increase
indicating that the prevalence of CDAD discharges is increasing. The CDAD death rate
per 10,000 discharged patients demonstrates that CDAD deaths are increasing in
Florida’s acute care hospitals.
Co-morbidities and what they mean
The data in this study was analyzed to determine if toxic megacolon and
perforated colon prevalence are also increasing. The analysis results demonstrate that
prevalence for these two co-morbidity conditions are not increasing. It is not known if
patients are dying faster and not having these conditions, if patients are becoming better
before these conditions are diagnosed, or if doctors are just not reporting these
conditions.
Summary of bias, confounding, and chance
This study was limited to patients discharged from Florida’s acute care hospitals.
This is important because information from nursing care facilities and federal hospitals is
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missing from the information that was provided. The results of this study should not be
used as a predictor of CDAD prevalence for nursing care facilities or federal hospitals in
Florida. This study also lacks the ability to be used as a comparison to other states in the
U.S.
The major confounder that could occur is age. The study intentionally grouped
the data for each year to reduce the effects of age as a confounder on the analyzed results.
Age affects mortality, but because we are estimating rates per year and comparing these
rates on an annual basis, and the age of the patient population does not change very much
over the years of this study, it is concluded that age and its effects as a confounding factor
has been controlled for during the analysis. This study further limits the affects of age by
stratifying the population into 11 age groups and looking at discharge and death trends
among the age groups.
Chance is not a factor in this study. All of the known patient discharge data from
acute care hospitals in Florida is included in this study, therefore, p-values are not
calculated because this study uses population data.
CONCLUSIONS
Prevalence of Clostridium difficile in Florida’s acute care hospitals is increasing.
The mortality of patients who have CDAD remains relatively constant except for patients
that are >70 that show an increasing mortality through the years of the study. This is in
contrast to a decreasing mortality for those patients that have no CDAD. These increases
make this a serious disease for persons hospitalized in Florida’s acute care facilities. This
study demonstrates that age is a factor for higher CDAD prevalence. The variables
length of hospital stay, race and gender show little affect on the increased prevalence
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Clostridium difficile infections. The ‘more virulent’ strain of CDAD most likely entered
Florida in the year 2001. The values and figures in this study provide the most current
available information for affects of this disease on patients discharged from Florida’s
acute care hospitals. The trends noted in this study show the disease prevalence to be
increasing and the emphasis should be to develop and implement preventative methods
that decrease the prevalence of CDAD.
RECOMMENDATIONS
Further explanation is needed to discuss the prevalence of CDAD. Adjusting this
study to further explain the prevalence at a county level would help to explain exactly
what areas of Florida are affected the most. Using the results of this statewide descriptive
study for an in depth analysis is recommended for individual hospitals to find ways to
reduce the prevalence of CDAD. This could be accomplished by creating a group of
hospitals to act as satellites for a CDAD analysis, make changes in the group of hospitals
that would decrease prevalence of CDAD, and compare the changed prevalence of
CDAD with hospitals that are not part of the satellite group. This CDAD analysis would
give opportunities for health care professionals to implement more effective methods of
treating the disease and preventing the disease from spreading to other patients.
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Figure 1: Florida hospital patients, median age, discharged with
and without CDAD, 1998-2004.
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Figure 2: Florida hospital patients, percent >60 years
old, discharged with and without CDAD, 1998-2004.
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Figure 3: Florida hospital patients, percent non-white,
discharged with and without CDAD, 1998-2004.
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Figure 4: Average length of hospital stay for CDAD and
non-CDAD discharged patients from Florida hospitals,
1998-2004.
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Table 5: Florida non-CDAD and CDAD patient’s average length of hospital stay, days,
1998-2004.

Year and
population
Age group

1998 non-CDAD
pop.

1998 CDAD
pop.

2004 non-CDAD
pop.

2004 CDAD
pop.

≤1

3.57

12.31

3.80

17.85

>1-10

3.96

11.33

3.41

12.52

>10-20

4.42

14.97

3.87

14.65

>20-30

3.33

12.54

3.52

13.26

>30-40

4.26

14.28

4.08

12.95

>40-50

4.94

14.13

4.88

13.61

>50-60

5.18

15.04

5.18

15.90

>60-70

5.43

14.46

5.33

14.61

>70-80

5.70

13.64

5.52

13.21

>80-90

5.98

12.31

5.70

11.40

>90

5.93

11.60

5.59

9.67

Total mean
Length of stay

4.94

13.47

4.88

13.07
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Appendix F

Figure 5: Florida average patient hospital cost at
discharge, $/patient, for CDAD and non-CDAD patients,
1998-2004.
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Figure 6: Florida hospital discharges, toxic
megacolon and perforated colon, for Clostridium
difficile positive patients, 1998-2004.
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Figure 7: Florida toxic megacolon and perforated
colon discharges per 1,000 positive CDAD discharged
patients, 1998-2004.
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Figure 8: Florida Clostridium difficile positive patients
discharged from hospitals, 1998-2004.
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Figure 9: Florida patients contracting CDAD per
1,000 discharged patients, 1998-2004.
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Figure 11: Patients discharged from Florida hospitals, positive for
Clostridium difficile, by age group, 1998-2004.
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Figure 12: Florida CDAD positive patients per 1,000 patients
discharged, by age group, 1998-2004.
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Figure 13: CDAD prevalence per 1,000 Florida discharged white
male patients 1998-2004.
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Figure 14: CDAD prevalence per 1,000 Florida discharged white
female patients, 1998-2004
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Appendix P

Figure 15: CDAD prevalence per 1,000 Florida discharged black male
patients, 1998-2004

20

1998
1999
2000
2001
2002
2003
2004

15

10

5

0
>80
-9

>90

0
>70
-8

0
>40
-5

78

0

0
>30
-4

Age group

>60
-7

0
>20
-3

>50
-60

0
>10
-2

0
>110

Prevalence per 1,000 discharged
black male patients

25

Appendix Q

Figure 16: CDAD prevalence per 1,000 Florida discharged black
female patients, 1998-2004.
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Appendix R
Figure 17: CDAD prevalence per 1,000 Florida discharged other
race male patients, 1998-2004.
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Appendix S

Figure 18: CDAD prevalence per 1,000 Florida discharged other
race female patients, 1998-2004.
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Appendix T

Figure 19: Florida hospital patients, percent mortality,
CDAD and non-CDAD, 1998-2004
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Appendix U

Figure 20: Florida hospital patients, percent mortality,
non-CDAD by 11 age groups, 1998-2004.
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Appendix V

Figure 21: Florida hospital patients, percent mortality,
CDAD positive patients by 11 age groups, 1998-2004.
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Appendix W
Table 8: The mortality percent for CDAD discharges in Florida acute care hospitals, by
age group, 1998-2004.
Age
Group

Year

1998

1999

2000

2001

2002

2003

2004

>1-10

3.53

0.93

1.85

0.82

0.76

0.69

0

>30-40

2.89

2.78

2.99

2.14

4.20

4.25

4.10

>50-60

8.89

7.19

7.44

6.97

6.75

7.10

6.41

>60-70

9.35

9.07

9.02

9.40

8.76

9.94

8.82

>70-80

10.2

10.2

10.4

10.4

12.3

10.7

11.1

>80-90

12.1

13.4

13.3

14.7

14.1

14.3

13.0

>90

15.1

15.8

13.2

18.5

18.4

18.0

18.6

Totals

9.48

9.70

9.69

10.4

10.8

10.7

10.1
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Appendix X
Table 9: Florida mortality of CDAD patients per 10,000 discharged patients, by age
group, 1998-2004.

Age
group

Year

1998

1999

2000

2001

2002

2003

2004

>1-10

0.74

0.24

0.47

0.22

0.22

0.21

0

>30-40

0.44

0.44

0.47

0.40

1.06

1.12

1.27

>50-60

2.66

2.07

2.42

2.81

3.59

4.29

4.40

>60-70

3.77

4.00

3.89

5.11

6.45

8.23

8.66

>70-80

4.52

5.82

5.82

7.88

12.9

13.3

15.7

>80-90

8.41

9.28

9.30

15.3

18.5

22.2

23.9

>90

10.4

11.7

10.6

20.3

24.4

28.2

32.6

Totals

3.23

3.41

3.40

4.88

6.60

7.49

8.20
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Appendix Y
Table 10: Discharges of Clostridium difficile in Florida’s acute care hospital, percent of discharges for each year, 1998-2004.

Age
Group

Year

Total
Number of
Discharges

1998
Discharges
(%)

1999
Discharges
(%)

2000
Discharges (%)

2001
Discharges
(%)

2002 Discharges (%)

2003 Discharges (%)

2004 Discharges
(%)

≤1

943

84 (1.17)

120 (1.58)

132 (1.68)

144 (1.31)

163 (1.11)

150 (0.87)

150 (0.74)

>1 - 10

844

85 (1.19)

108 (1.43)

108 (1.38)

131 (0.90)

144 (0.84)

152 (0.75)

>10 - 20

875

68 (0.95)

110 (1.45)

102 (1.30)

103 (0.94)

142 (0.97)

162 (0.94)

188 (0.93)

>20 - 30

1500

160
(2.24)

161 (2.13)

151 (1.92)

199 (1.81)

236 (1.61)

269 (1.57)

324 (1.60)

>30 - 40

3279

311
(4.35)

324 (4.28)

334 (4.25)

420 (3.83)

571 (3.91)

612 (3.57)

707 (3.50)

>40 - 50

5419

502
(7.02)

467 (6.16)

491 (6.25)

700 (6.38)

913 (6.24)

1073 (6.26)

1273 (6.30)

>50 - 60

7754

585
(8.18)

598 (7.89)

726 (9.25)

976 (8.89)

1362 (9.32)

1620 (9.44)

1887 (9.34)

>60 - 70

13284

1123
(15.7)

1246 (16.45)

1253 (16.0)

1638
(14.91)

2249 (15.4)

2596 (15.13)

3172 (15.7)

>70 - 80

25164

2157
(30.2)

2256 (29.78)

2268 (28.9)

3185
(29.0)

4361 (29.8)

5107 (29.8)

5830 (28.9)

>80 - 90

22039

1735
(24.3)

1806 (23.84)

1867 (23.8)

2894
(26.4)

3741 (25.6)

4513 (26.3)

5483 (27.14)

>90

4429

380 (5.01)

425 (6.01)

600 (5.46)

751 (5.13)

907 (5.28)

1035 (5.11)

Totals

85530

7576

7851

10980

14620

17153

20201

331
(4.64)
7149

122 (1.11)
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Appendix Z
Table 11: Total deaths for Florida non-CDAD discharged patients and the percent of
deaths per year, 1998-2004.
Age
Group

Year

Total
Number
of
Deaths
19982004

1998
Deaths
(%)

1999
Deaths
(%)

2000
Deaths
(%)

2001
Deaths
(%)

2002
Deaths
(%)

2003
Deaths
(%)

2004
Deaths
(%)

≤1

7422

964
(1.74)

1035
(1.81)

988
(1.78)

1096
(1.92)

1090
(1.93)

1161
(2.10)

1088
(2.02)

>1 - 10

1016

172
(0.31)

155
(0.27)

160
(0.29)

138
(0.24)

138
(0.24)

127
(0.23)

126
(0.23)

>10 - 20

2128

266
(0.48)

295
(0.52)

329
(0.59)

307
(0.54)

291
(0.52)

304
(0.55)

336
(0.62)

>20 - 30

4017

564
(1.02)

576
(1.01)

565
(1.02)

575
(1.01)

566
(1.00)

553
(1.00)

618
(1.15)

>30 - 40

9208

1428
(2.58)

1346
(2.36)

1359
(2.44)

1340
(2.35)

1282
(2.27)

1221
(2.21)

1232
(2.28)

>40 - 50

20247

2683
(4.84)

2656
(4.65)

2867
(5.16)

2934
(5.15)

3036
(5.38)

3020
(5.46)

3051
(5.66)

>50 - 60

32241

4258
(7.73)

4358
(7.63)

4424
(7.96)

4680
(8.21)

4740
(8.40)

4913
(8.89)

4868
(9.03)

>60 - 70

58684

8637
(15.6)

8708
(15.3)

8216
(14.8)

8342
(14.6)

8353
(14.8)

8184
(14.8)

8244
(15.3)

>70 - 80

111793

16484
(29.7)

16845
(29.5)

16273
(29.3)

16573
(29.1)

15939
(28.2)

15198
(27.5)

14481
(26.9)

>80 - 90

111357

15561
(28.1)

16323
(28.6)

15922
(28.6)

16209
(28.4)

16217
(28.7)

15795
(28.6)

15330
(28.4)

>90

32576

4361
(7.87)

4792
(8.39)

4493
(8.08)

4780
(8.39)

4802
(8.51)

4796
(8.68)

4552
(8.44)

Totals

390689

55416

57089

55596

56976

56454

55272

53926

88

Appendix AA

Age Group

Table 12: Florida total death numbers for the CDAD patients and the percent of death for
each year, 1998-2004.
Year

Total
Number
of Deaths
19982004

1998
deaths
(%)

1999
deaths
(%)

2000
deaths
(%)

2001
deaths
(%)

2002
deaths
(%)

2003
deaths
(%)

2004
deaths
(%)

0 (0)

0 (0)

0 (0)

4 (0.35)

4 (0.25)

1
(0.05)

3
(0.15)

9

3 (0.44)

1 (0.14)

2 (0.26)

1 (0.09)

1 (0.06)

1
(0.05)

0 (0)

>10 - 20

22

1 (0.15)

2 (0.27)

2 (0.26)

3 (0.26)

2 (0.13)

8
(0.44)

4
(0.20)

>20 - 30

49

6 (0.88)

8 (1.09)

6 (0.79)

5 (0.44)

9 (0.57)

11
(0.60)

4
(0.20)

>30 - 40

116

9 (1.33)

9 (1.22)

10 (1.31)

9 (0.79)

24
(1.52)

26
(1.42)

29
(1.42)

>40 - 50

266

22
(3.24)

26
(3.54)

32 (4.20)

34 (2.97)

45
(2.86)

56
(3.06)

51
(2.50)

>50 - 60

545

52
(7.67)

43
(5.85)

54 (7.10)

68 (5.94)

92
(5.84)

115
(6.28)

121
(5.92)

>60 - 70

1220

105
(15.5)

113
(15.4)

113
(14.8)

154
(13.5)

197
(12.5)

258
(14.1)

280
(13.7)

>70 - 80

2750

220
(32.4)

231
(31.4)

237
(31.1)

331
(28.9)

536
(34.0)

548
(29.9)

647
(31.7)

>80 - 90

3007

210
(31.0)

242
(32.9)

249
(32.7)

424
(37.1)

527
(33.5)

644
(35.2)

711
(34.8)

>90

771

50
(7.37)

60
(8.16)

56 (7.36)

111
(9.70)

138
(8.76)

163
(8.90)

193
(9.45)

Totals

8767

≤1

12

>1 - 10

678

735

761

89

1144

1575

1831

2043

